Protein kinase inhibitors against malignant lymphoma
暂无分享,去创建一个
[1] R. Advani,et al. The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study , 2010 .
[2] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[3] S. Treon,et al. Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study. , 2009 .
[4] Ronald Levy,et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.
[5] F. Jardin,et al. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial , 2010, Cancer Chemotherapy and Pharmacology.
[6] Christopher J. Chang,et al. Molecular Imaging: Editorial overview , 2010 .
[7] Michael L. Wang,et al. PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib , 2010 .
[8] Hermann Einsele,et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. , 2011, Blood.
[9] D. Moore,et al. Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma , 2008, Cancer.
[10] M. Valentine,et al. Sequence Correction , 1995, Science.
[11] F. Uckun,et al. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors , 2011, Arzneimittelforschung.
[12] J. Burger. Angiopoietin-2 in CLL. , 2010, Blood.
[13] A. Wellstein,et al. Recruitment of insulin receptor substrate-1 and activation of NF-κB essential for midkine growth signaling through anaplastic lymphoma kinase , 2007, Oncogene.
[14] R. Fonseca,et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Scott E. Smith,et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Ulrich,et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.
[17] H. Niiro,et al. Decision making in the immune system: Regulation of B-cell fate by antigen-receptor signals , 2002, Nature Reviews Immunology.
[18] T. Habermann,et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation , 2010, Cancer.
[19] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[20] B. Hennessy,et al. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. , 2011, The Journal of clinical investigation.
[21] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[22] T. Portis,et al. Epstein–Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway , 2004, Oncogene.
[23] L. Staudt,et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study , 2012 .
[24] L. Staudt,et al. Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.
[25] T. Habermann,et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma , 2010, Leukemia.
[26] L. Staudt,et al. The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL , 2011 .
[27] P. Richardson,et al. Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM) , 2008 .
[28] W. Leonard,et al. Jaks and STATs: biological implications. , 1998, Annual review of immunology.
[29] J. Dipersio,et al. A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies , 2008, Clinical Cancer Research.
[30] Pamela L. Schwartzberg,et al. TEC-family kinases: regulators of T-helper-cell differentiation , 2005, Nature Reviews Immunology.
[31] J. Byrd,et al. The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies , 2010 .
[32] F. Uckun,et al. Targeting Spleen Tyrosine Kinase (Syk) for Treatment of Human Disease , 2012 .
[33] J. Byrd,et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study , 2011 .
[34] Ralf Küppers,et al. Mechanisms of B-cell lymphoma pathogenesis , 2005, Nature Reviews Cancer.
[35] J. Moll,et al. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers , 2008, Expert opinion on therapeutic targets.
[36] T. Greiner,et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. , 1999, Blood.
[37] K. Parang,et al. Development of Src tyrosine kinase substrate binding site inhibitors. , 2008, Current opinion in investigational drugs.
[38] J. Vose,et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[40] W. Chan,et al. Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) , 2010 .
[41] J. Hutchcroft,et al. B lymphocyte activation is accompanied by phosphorylation of a 72-kDa protein-tyrosine kinase. , 1991, The Journal of biological chemistry.
[42] M. Morgan,et al. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? , 2000 .
[43] T. Habermann,et al. Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274). , 2006 .
[44] J. Byrd,et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. , 2012 .
[45] I. Lossos,et al. Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL) , 2011 .
[46] K. Anderson,et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. , 2010, Blood.
[47] N. Hay,et al. The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.
[48] J. Shah,et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] R. Ulrich,et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] V. Diehl,et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. , 2012, Blood.
[51] J. Friedberg,et al. Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study. , 2012 .
[52] P. Fenaux,et al. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia , 2008, British journal of haematology.
[53] F. Uckun,et al. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas , 2010, Expert review of anticancer therapy.
[54] H. Kantarjian,et al. The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients , 2012 .
[55] N. Vasudeva,et al. Chemical Composition and Antimicrobial Activity of Essential Oil of Citrus limettioides Tanaka , 2012 .
[56] T. Kurosaki,et al. B Cell Antigen Receptor-Induced Activation of Akt Promotes B Cell Survival and Is Dependent on Syk Kinase1 , 2000, The Journal of Immunology.
[57] J. Raemaekers,et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] A. Feldman,et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. , 2011, The Lancet. Oncology.
[59] A. Tolcher,et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] H. Kantarjian,et al. Potential role of sorafenib in the treatment of acute myeloid leukemia , 2008, Leukemia & lymphoma.
[61] J. D. Dal Porto,et al. B Cell Antigen Receptor Signaling: Roles in Cell Development and Disease , 2002, Science.
[62] H. Burris,et al. 280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States , 2008 .
[63] Timothy J. Yeatman,et al. A renaissance for SRC , 2004, Nature Reviews Cancer.
[64] Jeffrey A Jones,et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. , 2012 .
[65] Michael L. Wang,et al. Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up , 2012 .
[66] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[67] F. Uckun,et al. Targeting SYK kinase‐dependent anti‐apoptotic resistance pathway in B‐lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic , 2010, British journal of haematology.
[68] Juswinder Singh,et al. Targeted covalent drugs of the kinase family. , 2010, Current opinion in chemical biology.
[69] C. A. Carter,et al. Therapeutic potential of natural compounds that regulate the activity of protein kinase C. , 2004, Current medicinal chemistry.
[70] Beverly A. Teicher,et al. Antiangiogenic effects of a protein kinase Cβ-selective small molecule , 2001, Cancer Chemotherapy and Pharmacology.
[71] B. Coiffier,et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] N. Schmitz,et al. CNS Disease In Younger Patients ( , 2010 .
[73] P. Richardson,et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] G. Laurent,et al. Syk-dependent mTOR activation in follicular lymphoma cells. , 2006, Blood.
[75] T. Habermann,et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma , 2010, American journal of hematology.
[76] G. Superti-Furga,et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib , 2007, Proceedings of the National Academy of Sciences.
[77] Maurizio Rocchetti,et al. Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors , 2008 .
[78] Shinji Yamazaki,et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.
[79] H. Kantarjian,et al. The role of Src in solid and hematologic malignancies , 2006, Cancer.